A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.
|Podcasts|September 30, 2022
Pap Talk: Medications for early pregnancy loss
Author(s)Lindsey Carr, Editor
In this episode of Pap Talk, Amy Levi, CNM, WHNP-BC, FACNM, FAAN, Albers Endowed Professor of Midwifery at the University of New Mexico College of Nursing, sits down to discuss her presentation at the NPWH 25th Annual Premier Women's Healthcare Conference on medications for early pregnancy loss.
Advertisement
Advertisement
Related to this article
Fezolinetant was linked to VMS and sleep improvements by week 4 in the real-world OPTION-VMS study, presented at the International Menopause Society World Congress.
Wen Shen, MD, highlights perimenopause as an important period for identifying health risks and supporting healthy aging beyond the menopausal transition.
A global consensus published in The Lancet has officially renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome, a change with broad implications for diagnosis, care, and cardiometabolic screening.
The Preeclampsia Foundation released 2 videos on postpartum recovery and long-term health after HDP.
AJOG research shows a cytokine storm could be detectable in maternal blood before the clinical onset of AFE.
CDC data show gestational hypertension rose 73% from 2016 to 2024, affecting 1 in 10 US mothers giving birth.
Missed the updated IDSA histoplasmosis guideline? This easy-to-read FAQ covers what clinicians caring for pregnant patients need to know.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Wen Shen, MD, on recognizing perimenopause as a window for healthy aging
2
FAQ: What does the rename from PCOS to PMOS mean for your patients?
3
Preeclampsia Foundation launches postpartum recovery videos for HDP
4
FDA grants priority review to elinzanetant for VMS in women receiving endocrine therapy for breast cancer
5